Please wait while we gather the requested information from the database...



Get Involved
| Contact Us | Join SOT | Site Map | Help
Submit Button for the Search Form
 
Login: Email address
Password
Submit Button for the Login Form
Forgot your Password?

Meet The Leaders

2013–2014 Council



Lois D. Lehman-McKeeman
President
(2013–2014)

Bristol-Myers Squibb Company

Experience: Dr. Lehman-McKeeman is currently a Distinguished Research Fellow in Discovery Toxicology at the Bristol-Myers Squibb Company in Princeton, New Jersey. She was employed in the Human and Environmental Safety Division of the Procter and Gamble Company for 15 years prior to joining Bristol-Myers Squibb in 2001. Dr. Lehman-McKeeman has active research interests and programs broadly in biochemical mechanisms of toxicity, with emphasis on secondary mechanisms of carcinogenesis. She is also working to develop and apply metabonomic and transcriptomic technologies to mechanistic toxicology. She has published extensively in these fields. She has been active professionally in the Society of Toxicology (SOT) serving as the current President and on numerous SOT committees, and she held elective office in the SOT as Councilor from 2000–2002 and the SOT Awards Committee from 2008–2010. In 2003, she was appointed Editor of Toxicological Sciences, a position she held through 2011, and she serves on a number of other editorial boards.



Norbert E. Kaminski
Vice President
(2013–2014)

Michigan State University

Experience: Dr. Kaminski is a professor of pharmacology and toxicology and director of the Center for Integrative Toxicology at Michigan State University. He holds joint appointments in the College of Human Medicine and Veterinary Medicine at Michigan State University. Dr. Kaminski joined the Michigan State faculty in 1993. Dr. Kaminski held the rank of assistant professor at the Medical College of Virginia in the Department of Pharmacology and Toxicology from 1985–1999. He received his doctorate degree in toxicology and physiology from North Carolina State University in 1985 and his master’s degree from North Carolina State University in toxicology in 1981. He is a founding member of the Editorial Board for Nonlinearity in Biology, Toxicology and Medicine, and is currently on the editorial board for the journals Toxicology and Journal of Immunotoxicology. Dr. Kaminski served as a member of Council as well as Chair of the Membership Committee for the Society on NeuroImmune Pharmacology. He also serves on the Board of Trustees for the International Life Sciences Institute (ILSI) Health and Environmental Sciences Institute (HESI) and currently serves as treasurer. He has been a member of various advisory panels including the National Academy of Sciences and the US EPA Science Advisory Board and also has served on numerous peer review panels.



Peter L. Goering
Vice President-Elect
(2013–2014)

Experience: Dr. Goering is currently a Research Toxicologist and Lab Leader, Laboratory of Toxicology and Biocompatibility, at the US FDA, Center for Devices and Radiological Health, in Silver Spring, Maryland. He earned his PhD from the University of Kansas Medical Center, and did a postdoctoral fellowship at the NIEHS focusing on the toxicology of metals and metal defense mechanisms. At the US FDA, his research interests include nanotoxicology, evaluating liver and kidney toxic injury, elucidating new biomarkers of toxicity, and understanding mechanisms of metal toxicity. Dr. Goering has co-authored over 80 peer-reviewed publications and book chapters, is a Diplomate of the American Board of Toxicology (1994), and was named a Fellow of Academy of Toxicological Sciences (2006). He serves as an adjunct professor in the Toxicology Program at the University of Maryland and The George Washington University’s Department of Biological Sciences. He has been active professionally in the Society of Toxicology (SOT) in several capacities. He is a member of the National Capital Area Chapter (NCAC-SOT) Regional Chapter, and served as its President (2000–2001). He served as a Councilor (1992–1994) and President (1999–2000) of the SOT Metals Specialty Section; SOT Nominating Committee member (2004–2006); and Regulatory Affairs and Legislative Assistance Committee member (2003–2006), Chairperson (2004–2006).



Denise Robinson Gravatt
Treasurer
(2013–2015)

Pfizer

Experience: Dr. Robinson Gravatt is currently a senior director and head of science and technology in Drug Safety R&D at Pfizer in Groton, Connecticut. She is responsible for broad science-based research strategies across the global Pfizer organization to address long-standing safety issues related to drug development. These research strategies encompass internal laboratory research and external technology development and investment strategies, including postdoctoral fellowships, external collaborations and other partnerships. Prior to joining Pfizer in 2002, Dr. Robinson Gravatt was the founding director of the ILSI Health and Environmental Sciences Institute, a non-profit organization devoted to advancing the application of toxicological sciences to risk assessment and risk management. She serves on the Advisory Committee of the Critical Path Institute’s Predictive Safety Testing Consortium, the Steering Committee and Scientific Advisory Committee for Innovative Medicine Initiative’s SAFE-T Consortium, and Program Committee for Toxicology Forum. She obtained her doctorate degree in pharmacology from Georgetown University in 1986.



Judith T. Zelikoff
Secretary
(2012–2014)

New York University School of Medicine

Experience: Dr. Zelikoff has extensive experience in an advisory and leadership capacity as reflected by her membership on two National Institutes of Health Study Sections. She is member of the National Institutes of Health College of Scientific Reviewers, National Academy of Science Committees, the National Toxicology Program (Board Member) Scientific Advisory Board, a NASA Moon Dust Panel (Chair), United Nations Atmospheric Brown Cloud Human Health Effects Panel, and the New Jersey Department of Environmental Protection Human Health Committee. Dr. Zelikoff is heavily involved with students both in teaching (three graduate courses in toxicology and immunotoxicology) and in mentoring of masters, doctoral, and postdoctoral trainees in the area of developmental immunotoxicology of inhaled smoke mixtures and nanomaterials. In addition, as Director of Community Outreach for the NYU Department of Environmental Medicine NIEHS Center, she led a laboratory research mentorship program for high school and college students. Dr. Zelikoff has organized a number of international and national meetings in immunotoxicology, as well as developed immunotoxicology courses, in India, Thailand, New Zealand, and Australia.



Leigh Ann Burns Naas
Secretary-Elect
(2013–2014)

Gilead Sciences, Inc

Experience: Dr. Burns Naas is Vice President of Drug Safety Evaluation at Gilead Sciences, Inc. She was a Therapeutic Area Leader for Infectious Disease, Vaccines, and Oncology at Pfizer in Drug Safety Research and Development over the 10 years preceding her move to Gilead. Prior to that, she worked as a product toxicologist in Health, Environmental, and Regulatory Affairs at Dow Corning Corporation in Midland, Michigan. Throughout her career, her work has focused on strategic aspects and the design of safety programs to support chemical product development and registration, and to support the clinical development and licensure for small molecules and biotherapeutics, including vaccines. Dr. Burns Naas has been active in both the Society of Toxicology (SOT) and the American College of Toxicology (ACT) serving on several committees both elected and appointed in both, and serves on the Editorial Board for two journals. She has demonstrated a long commitment to promoting advancements in basic and applied toxicology, the impact of science on human and environmental health across multiple scientific organizations and in the literature, and to participating in the training/education of the next generation of toxicologists. Dr. Burns Naas received her doctorate degree in pharmacology and toxicology from the Medical College of Virginia/VCU in 1992 with an emphasis on immunotoxicology.



William Slikker Jr.
Past President
(2013–2014)

US Food and Drug Administration
National Center for Toxicological Research

Experience: Dr. Slikker is currently the Director of the US FDA’s National Center for Toxicological Research (NCTR) and an Adjunct Professor of Pediatrics and Pharmacology & Toxicology at UAMS. He has served as President of the Teratology Society and the Academy of Toxicological Sciences. In addition, Dr. Slikker also has served on advisory panels for HESI/ILSI, CIIT, US EPA, NIEHS, NIH, NAS, and WHO.



Lorrene A. Buckley
Councilor
(2012–2015)

Eli Lilly & Company

Experience: Dr. Buckley earned her master’s degree in toxicology at the University of Arizona and her doctorate degree at the University of North Carolina, Chapel Hill. Dr. Buckley’s diversity of professional experience as a toxicologist is reflected in her work spanning basic research on the inhalation toxicity of industrial chemicals, toxicology and risk assessment in the agro-chemical industry, and pharmaceutical safety assessment. In her current position as research fellow at Eli Lilly & Company, she is responsible for the design and execution of nonclinical safety assessment programs as well as for nonclinical aspects of global regulatory submissions and interactions for a variety of drugs in the development and commercialization phases. Dr. Buckley holds elected positions serving in the Society of Toxicology and the American College of Toxicology.



Myrtle A. Davis
Councilor
(2013–2016)

Toxicology and Pharmacology
National Cancer Institute

Experience: Dr. Davis earned a PhD in Toxicology from the University of Illinois Champaign-Urbana in and completed a postdoctoral fellowship in Toxicologic Pathology at the University of Maryland. She completed undergraduate work in chemistry and obtained her Doctor of Veterinary Medicine degree from Tuskegee University School of Veterinary Medicine. Dr. Davis. is the currently the Branch Chief for Toxicology and Pharmacology in the Developmental Therapeutics Program of the Division of Cancer Diagnostics and Treatment of the NCI. Dr. Davis moved to NIH and the National Cancer Institute from Lilly Research Labs, Eli Lilly and company where she held the position of Research Advisor in the Investigative Toxicology Group. Prior to taking the position at Eli Lilly, Dr. Davis was an Associate Professor in the Department of Pathology at the University of Maryland, School of Medicine where she had an active research program exploring mechanisms of toxicant-induced apoptosis and the role of protein phosphorylation.



Dori R. Germolec
Councilor
(2011–2014)

Experience: Dr. Germolec currently serves as the Immunology discipline leader for the National Toxicology Program (NTP) and directs the NTP’s efforts to design, interpret and report studies that assess the potential for chemicals to modulate immune responses. She is particularly interested in persistent immunologic effects following in utero chemical exposure. She also serves as a project leader for toxicology studies and is leading the NTP research efforts to evaluate the health effects of exposure to molds. Dr. Germolec served as the group leader of the Environmental Immunology Laboratory within the Laboratory of Molecular Toxicology at the National Institute of Environmental Health Sciences from 1995 to 2005. Her research interests include: investigating the interaction between environmental, industrial, and pharmacologic agents and the immune system, and defining the cellular and molecular role of cytokines in toxicity in a variety of organ systems including the skin, lung, and liver.



John C. Lipscomb
Councilor
(2011–2014)

Federal Scientist

Experience: Dr. Lipscomb is a toxicologist and risk assessor. His activities and interests center on replacing default options with science-based decisions. He has over 20 years experience in toxicology and risk assessment, including the US EPA, US FDA/NCTR and uniformed service in the US Air Force. He has published 62 articles, 10 book chapters, 31 government reports, edited a text on Toxicokinetics and Risk Assessment, written risk assessment guidance for the US EPA and the WHO’s International Programme on Chemical Safety, and served as a technical advisor to the American Water Works Association for its research on drinking water disinfection byproducts.



Ivan Rusyn
Councilor
(2012–2015)

University of North Carolina Chapel Hill
Department of Environmental Sciences and Engineering

Experience: Dr. Rusyn is a professor in the Department of Environmental Sciences and Engineering at the University of North Carolina. From 2007–2010, he was an Associate Professor with tenure at the University. He is a member of the Curriculum in Toxicology at UNC and is the director of the Carolina Center for Computational Toxicology at the UNC Gillings School of Global Public Health. He is a full member of the UNC Lineberger Comprehensive Cancer Center, Bowles Center for Alcohol Studies, the Center for Environmental Health and Susceptibility, and the Carolina Center for Genome Sciences. He received his doctorate degree from the University of North Carolina, Chapel Hill and his medical degree with honors from the Ukrainian State Medical University in 1994.



John A. Wisler
Councilor
(2013–2016)

Amgen, Inc

Experience: Dr. Wisler is currently a Scientific Director in Toxicology Sciences at Amgen in Thousand Oaks, California. Before joining Amgen in 2003, he was a Toxicology Director with Allergan; a Senior Toxicologist with the Procter and Gamble Company; an Associate Director with a CRO (IRDC/ MPI); and was a National Research Council postdoctoral fellow with the US Army Institute of Chemical Defense. He has held leadership positions in SOT Regional Chapters and Specialty Sections; served on the American Board of Toxicology (ABT) board of directors; and is a Past President of ABT. He has over 20 years of experience in scientific toxicology leadership roles including managing toxicology facilities and staff, consumer product risk assessment as well as drug discovery safety evaluations through post marketing pharmaceutical regulatory activities for both large and small molecule drug modalities. He received his doctorate degree in toxicology from Indiana University (School of Medicine) in 1988.



Shawn Douglas Lamb
Executive Director

Experience: Ms. Lamb has been Deputy Director and Executive Director of SOT since 1991. In addition, she has been President, Association Innovation and Management (AIM), an association management company providing administrative services to the toxicology community, since 1998. She received her BIS in Business Communications, George Mason University, 1989.




SOT —Dedicated to Creating a Safer and Healthier World by Advancing the Science of Toxicology.

© 2014 Society of Toxicology. All rights reserved.

Privacy Policy and Disclaimer | Contact Us